NCT00039429 2023-06-22
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
10 trialsNCT00134056 2021-10-27
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
SWOG Cancer Research Network
Phase 3 Completed
NCT00653328 2012-05-23
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00046943 2011-02-21
Atrasentan in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00181558 2010-05-10
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
Massachusetts General Hospital
Phase 2 Completed
NCT00017264 2009-01-13
Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00127478 2007-11-29
A Long Term Safety Study With Atrasentan
Abbott
Phase 2/3 Completed
NCT00036556 2007-08-15
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
Abbott
Phase 3 Completed
NCT00036543 2006-08-15
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
Abbott
Phase 3 Completed
NCT00038662 2006-08-15
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
Abbott
Phase 2 Completed